Ajanta Pharma launches Omeprazole and Sodium Bicarbonate Capsules in US Market

18 Jul 2016 Evaluate

Ajanta Pharma has received the final approval from US Food and Drug Administration (US FDA) and launched Omeprazole and Sodium Bicarbonate Capsules in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. It is a bioequivalent prescription generic version of Zegerid and the company has launched the product in 2 strengths 20mg/1100mg & 40mg/1100mg capsules.

Omeprazole and Sodium Bicarbonate Capsules is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 11 ANDAs; tentative approvals for 1 ANDA; and 14 ANDAs are under review with US FDA. 

Ajanta Pharma Share Price

2638.75 12.50 (0.48%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×